https://pharmadog.xyz/news/627771 pharmadog en 2026-11-02T12:28:16.000Z FDA accepts review of Biohaven’s ataxia drug, boosting shares as ArriVent’s lung cancer trial miss drags its stock down https://pharmadog.xyz/news/627747 pharmadog en 2026-11-02T12:00:45.000Z CinRx partners with Graviton Bioscience to target ROCK2 in pulmonary arterial hypertension and other cardiovascular diseases https://pharmadog.xyz/news/627307 pharmadog en 2026-11-02T10:00:00.000Z Pharma leaders turn to integrated scenario modeling as US MFN pricing reshapes global launch strategies https://pharmadog.xyz/news/627287 pharmadog en 2026-11-02T09:30:00.000Z STAT calls for input on mitochondrial replacement therapy used in fertility tourism https://pharmadog.xyz/news/627288 pharmadog en 2026-11-02T09:30:00.000Z Kymera Therapeutics to unveil mid‑stage eczema trial data, aiming to challenge Dupixent https://pharmadog.xyz/news/627289 pharmadog en 2026-11-02T09:30:00.000Z Cancer can be treated safely during pregnancy, says maternal-fetal specialist https://pharmadog.xyz/news/627290 pharmadog en 2026-11-02T09:30:00.000Z U.S. Health Care System's Economics Are Broken, Says Ascendiun CEO https://pharmadog.xyz/news/627291 pharmadog en 2026-11-02T09:30:00.000Z Women travel abroad for unproven three-parent IVF marketed to older patients https://pharmadog.xyz/news/626823 pharmadog en 2026-11-02T07:04:00.000Z Top pharma firms line up for Summit Therapeutics' ivonescimab after strong China Phase 3 data https://pharmadog.xyz/news/626824 pharmadog en 2026-11-02T07:00:00.000Z FDA issues draft guidance to streamline approval of personalized gene therapies https://pharmadog.xyz/news/626655 pharmadog en 2026-11-02T06:01:00.000Z Saudi Arabia pushes ahead with biotech hub despite regional instability https://pharmadog.xyz/news/627554 pharmadog en 2026-11-02T05:47:00.000Z InventisBio's Phase 3 Trial Shows Nomelcitinib Achieves Over 70% PASI-90 Response in Chinese Psoriasis Patients https://pharmadog.xyz/news/626487 pharmadog en 2026-11-02T05:09:00.000Z BridgeBio eyes first FDA approval for limb-girdle muscular dystrophy therapy